Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Suganami

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Journal of Diabetes Investigation|October 17, 2017
Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baselineKazuyuki Tobe, Hideki Suganami, Kohei Kaku
Journal of Pharmacological Sciences|February 24, 2006
QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeysHiroyuki Sasaki, Noritsugu Shimizu, Hideki Suganami, et al.
Clinical and Translational Science|July 30, 2024
Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studiesTomohiro Kamimura, Neil Hounslow, Hideki Suganami, et al.
Plos One|September 15, 2015
Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical StudyHiroko Nakagawa, Noriko Koizumi, Naoki Okumura, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetesKiyohide Nunoi, Yuichi Sato, Kohei Kaku, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight lossYuichi Sato, Kiyohide Nunoi, Kohei Kaku, et al.
Journal of Clinical Lipidology|August 27, 2025
Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insightsRyohei Tanigawa, So Nagai, Hirokazu Takahashi, et al.
Diabetes, Obesity & Metabolism|April 5, 2019
Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic statusKiyohide Nunoi, Yuichi Sato, Kohei Kaku, et al.
Journal of Atherosclerosis and Thrombosis|April 21, 2015
Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial HypercholesterolemiaMariko Harada-Shiba, Osamu Arisaka, Akira Ohtake, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
Current Practice in Japan for the Prevention and Treatment of Missing Data in Confirmatory Clinical Trials: A Survey of Japanese and Foreign Pharmaceutical ManufacturersShiro Tanaka, Satoru Fukinbara, Satoru Tsuchiya, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Journal of Diabetes Investigation|October 17, 2017
Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baselineKazuyuki Tobe, Hideki Suganami, Kohei Kaku
Journal of Pharmacological Sciences|February 24, 2006
QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeysHiroyuki Sasaki, Noritsugu Shimizu, Hideki Suganami, et al.
Clinical and Translational Science|July 30, 2024
Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studiesTomohiro Kamimura, Neil Hounslow, Hideki Suganami, et al.
Plos One|September 15, 2015
Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical StudyHiroko Nakagawa, Noriko Koizumi, Naoki Okumura, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetesKiyohide Nunoi, Yuichi Sato, Kohei Kaku, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight lossYuichi Sato, Kiyohide Nunoi, Kohei Kaku, et al.
Journal of Clinical Lipidology|August 27, 2025
Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insightsRyohei Tanigawa, So Nagai, Hirokazu Takahashi, et al.
Diabetes, Obesity & Metabolism|April 5, 2019
Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic statusKiyohide Nunoi, Yuichi Sato, Kohei Kaku, et al.
Journal of Atherosclerosis and Thrombosis|April 21, 2015
Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial HypercholesterolemiaMariko Harada-Shiba, Osamu Arisaka, Akira Ohtake, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
Current Practice in Japan for the Prevention and Treatment of Missing Data in Confirmatory Clinical Trials: A Survey of Japanese and Foreign Pharmaceutical ManufacturersShiro Tanaka, Satoru Fukinbara, Satoru Tsuchiya, et al.
Pageof 7